Does your child or teen suffer from moderate or severe migraine?

Now enrolling: a clinical study to evaluate the safety and efficacy of a dissolving tablet called rimegepant in children and teens 12 to 17 years old with moderate or severe migraine. Rimegepant is approved by the US Food and Drug Administration (FDA) for the acute treatment of migraine in adults.

To be eligible for this study, participants must:

  • Be 12 to 17 years old
  • Have a history of migraine for 6 months or longer
  • Have a history of 1 to 8 moderate or severe migraine attacks (lasting more than 3 hours without treatment) per month during the past 2 months
  • Be able to understand the assent form and have parent(s)/caregiver(s) who can give informed consent

This is not a complete list of study requirements. The study doctor will review all requirements with you and your child or teen.

To learn more about this study, contact:

Ewa Karlsson, phone 0732-300 450 or email ewa.karlsson@probare.se